Selank

Selank (TP-7) was developed in Russia as a stabilized analog of tuftsin — a naturally occurring tetrapeptide with immunomodulatory and behavioral activity. The stabilization modifications (adding three amino acids to the tuftsin sequence) significantly extend its biological half-life and increase CNS penetration compared to natural tuftsin. Selank is registered as an anxiolytic drug in Russia (trade name Selanc), where it is used clinically for generalized anxiety disorder, neurasthenia, and stress-related conditions. This registration gives it a more established regulatory history than most research peptides, though Western regulatory bodies have not reviewed or approved it. The compound's appeal in the research community lies in its specific profile: meaningful anxiety reduction without sedation, cognitive impairment, or addiction potential — a set of characteristics that distinguishes it from benzodiazepines (the standard pharmaceutical anxiolytic class) and aligns with what many users describe as "anxiolytic without feeling drugged."

Anxiety reduction without sedation is the primary documented benefit. Unlike benzodiazepines that cause sedation and cognitive impairment alongside anxiolysis, Selank's GABA modulation is more selective and its additional serotonin and dopamine activity contributes a mood-brightening component rather than a depressant one. Users consistently report reduced anxiety with maintained cognitive clarity. Cognitive enhancement — particularly in attention, memory consolidation, and processing speed — has been demonstrated in Russian clinical studies. This nootropic component may reflect BDNF (brain-derived neurotrophic factor) upregulation, a mechanism shared with other peptide nootropics like Semax. No addiction or withdrawal is a critical safety advantage. Selank does not cause receptor downregulation leading to physical dependence or withdrawal on cessation — a major clinical limitation of benzodiazepines. This makes it potentially suitable for longer-term or intermittent use without tolerance concerns. Immunomodulatory activity inherited from tuftsin is a secondary benefit — Selank has been shown to modulate interleukin levels and T-cell activity, adding an immune support dimension to its anxiolytic profile.

Selank has an excellent safety profile in both Russian clinical data and extensive anecdotal use. No serious adverse effects have been documented in published literature or widespread anecdotal reports. Mild fatigue or drowsiness has been reported by some users at higher doses, suggesting a dose-dependent sedating component at supraphysiological levels despite the generally non-sedating profile. Nasal irritation from repeated intranasal administration can occur with the nasal spray form. The primary uncertainty is long-term consequences — while short-term use has an established safety record, multi-year continuous use in healthy individuals hasn't been studied.

Nasal spray (most common): 250–3000 mcg/day, typically delivered as 250–500 mcg per nostril, 1–3 times daily. The nasal spray form is convenient and avoids injections while providing meaningful brain delivery via the olfactory pathway. Injection (SubQ): 250–500 mcg per injection, 1–2 times daily. Injection provides more reliable systemic delivery but is less convenient for an anxiolytic compound used throughout the day. As-needed use: Many users take Selank situationally before anxiety-provoking events (presentations, social situations) rather than on a daily schedule. This intermittent use approach avoids any tolerance concerns. Stacking timing: When combined with Semax (a common nootropic combination), both are typically administered in the morning, with Selank repeated in the afternoon if anxiety management is needed through the workday.

Russia: Registered pharmaceutical drug (Selanc). Available through medical channels. United States: Research chemical — no FDA approval, no controlled substance scheduling. Legal to purchase for research. WADA: Not on the prohibited list. No performance-enhancing rationale for restriction.

Selank + Semax: The most common nootropic combination. Semax provides focus, BDNF upregulation, and cognitive stimulation; Selank provides anxiolysis to balance any Semax-related anxiety. Together they address both cognitive performance and mood regulation — often described as complementary halves of a cognitive optimization protocol. Selank alone: For individuals whose primary goal is anxiety management without cognitive enhancement, Selank alone is appropriate and avoids unnecessary complexity.

Selank — Common Questions